Pharma

2024 - 12 - 20

Post cover
Image courtesy of "GlobeNewswire"

Nxera Pharma to Present at the 43rd Annual J.P. Morgan Healthcare ... (GlobeNewswire)

Tokyo, Japan and Cambridge, UK, 20 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei...

Post cover
Image courtesy of "Yahoo Finance UK"

Nxera Pharma to Present at the 43rd Annual J.P. Morgan Healthcare ... (Yahoo Finance UK)

Tokyo, Japan and Cambridge, UK, 20 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei ...

Setback for UK pharma as government sets unexpectedly high ... (pharmaceutical-technology.com)

The UK's DHSC has announced its anticipated 2025 headline payback rate for new medicines under the 2024–2028 VPAG.

Pharma Shifts to Needle-Free Injectors: Microneedle Devices Set for ... (Business Wire)

The needle-free drug injection system market is expected to reach USD 606 million in the current year and is anticipated to grow at a CAGR of 4% to 2035.

Post cover
Image courtesy of "PharmaLive"

Five data-driven media planning principles for pharma marketers in ... (PharmaLive)

When it comes to media strategy, the line between “spending” and “investing” can be as hazy as a misty morning. The difference? Spending is throwing money ...

Sorriso Pharma's UC treatment hits Phase Ib endpoints (Clinical Trials Arena)

Sorriso Pharmaceuticals announced that it is looking to move to Phase II after its ulcerative colitis treatment saw success over placebo.

Ropes & Gray Profiled in The American Lawyer for Winning Pharma ... (Ropes & Gray LLP)

A collaborative approach to advising health care and life sciences clients worldwide earned Ropes & Gray honors as The American Lawyer 2024 Industry Awards ...

Post cover
Image courtesy of "Pharmaceutical Executive"

Pharma Pulse 12/20/24: Trends in Enterprise Value Growth and ... (Pharmaceutical Executive)

Anna-Maria Hoffmann-Vold, MD, PhD, discusses progressive pulmonary fibrosis, its primary causes and the key risk factors contributing to its development and ...

Post cover
Image courtesy of "Yahoo Movies"

Setback for UK pharma as government sets unexpectedly high ... (Yahoo Movies)

Once VPAG was introduced in early 2024, the initial headline payback value was only 15.1% for newer medicines in Q2–Q4.

Post cover
Image courtesy of "Business Wire"

TME Pharma Provides Results of Fourth Exercise of Warrants Z (Business Wire)

Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for trea.

Explore the last week